Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
Submitted by
admin
on July 18, 2018 - 9:29am
Source:
CP Wire
News Tags:
Immunomedics
FDA
sacituzumab govitecan
triple negative breast cancer
Headline:
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
snippet:
PDUFA target date is 1/18/19
Sacituzumab govitecan is an antibody drug conjugate (ADC)
If appproved it would be the first ADC approved for mTNBC
Company has another ADC in Ph II for metastatic colorectal cancer
Do Not Allow Advertisers to Use My Personal information
